Unknown PHASE4 INTERVENTIONAL 1-arm NCT01649245

Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C (HAPIC)

Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial

Sponsor: MinaPharm Pharmaceuticals

Conditions Chronic Hepatitis C

Interventions Reiferon retard

Updated 5 times since 2017 Last updated: Jan 12, 2013 Started: Aug 31, 2012 Primary completion: Aug 31, 2014 Completion: Aug 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Chronic Hepatitis C, this trial is ongoing. The trial is conducted by MinaPharm Pharmaceuticals and has accumulated 5 data snapshots since 2012. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MinaPharm Pharmaceuticals

Data source: MinaPharm Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shebin El-Kom, Egypt